Koru Med Sys Financials
Koru Med Sys (KRMD) reported $41.1M in revenue for fiscal year 2025, up 22.2% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Revenue growth is finally reaching the income statement, with losses shrinking faster than sales rise and cash burn nearly gone.
A roughly flat gross margin near60% paired with operating loss improvement to-$3.0M shows the recent progress is mostly fixed-cost absorption as volume scales, not a wholesale change in unit economics. Cash quality improved too: operating cash flow turned positive at$462K while free cash flow stayed slightly negative at-$470K , so reinvestment rather than the core business is the main remaining drain.
The balance sheet is still equity-funded because there is no long-term debt and liabilities remain modest, but the cash reserve has fallen to
Liquidity is no longer exceptionally loose: the current ratio moved down to 2.4x from 7.8x as excess cash was used and receivables became a larger part of current assets. In other words, day-to-day execution now matters more than balance-sheet surplus; collections and inventory discipline are becoming more important than simply having cash on hand.
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Koru Med Sys's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Koru Med Sys scores 8.02, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($148.7M) relative to total liabilities ($11.2M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Koru Med Sys passes 4 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 3 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), 1 of 2 efficiency signals pass.
Koru Med Sys reported a net loss of $2.6M while generating $462K in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Koru Med Sys generated $41.1M in revenue in fiscal year 2025. This represents an increase of 22.2% from the prior year.
Koru Med Sys's EBITDA was -$2.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 61.1% from the prior year.
Koru Med Sys reported -$2.6M in net income in fiscal year 2025. This represents an increase of 56.5% from the prior year.
Koru Med Sys earned -$0.06 per diluted share (EPS) in fiscal year 2025. This represents an increase of 53.8% from the prior year.
Cash & Balance Sheet
Koru Med Sys recorded an outflow of $470K in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents an increase of 70.9% from the prior year.
Koru Med Sys held $8.9M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Margins & Returns
Koru Med Sys's gross margin was 62.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 1.1 percentage points from the prior year.
Koru Med Sys's operating margin was -7.2% in fiscal year 2025, reflecting core business profitability. This is up 11.9 percentage points from the prior year.
Koru Med Sys's net profit margin was -6.4% in fiscal year 2025, showing the share of revenue converted to profit. This is up 11.6 percentage points from the prior year.
Koru Med Sys's ROE was -15.5% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 20.6 percentage points from the prior year.
Capital Allocation
Koru Med Sys invested $4.4M in research and development in fiscal year 2025. This represents a decrease of 16.6% from the prior year.
Koru Med Sys invested $933K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 28.1% from the prior year.
Not reported for fiscal year 2025.
KRMD Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $45.1M | $41.1M+22.2% | $33.6M+18.0% | $28.5M+2.2% | $27.9M+18.8% | $23.5M-2.8% | $24.2M+4.4% | $23.2M+33.5% | $17.4M+41.2% | $12.3M+0.4% | $12.2M+8.9% | $11.2M+29.3% | $8.7M+12.0% | $7.8M+21.5% | $6.4M+29.9% | $4.9M |
| Cost of Revenue | $16.9M | $15.5M+26.1% | $12.3M+4.3% | $11.8M-5.7% | $12.5M+28.9% | $9.7M+5.2% | $9.2M+11.2% | $8.3M+27.0% | $6.5M+38.5% | $4.7M+1.7% | $4.6M+1.9% | $4.6M+34.5% | $3.4M+20.2% | $2.8M+25.2% | $2.3M+35.9% | $1.7M |
| Gross Profit | $28.2M | $25.6M+20.0% | $21.3M+27.7% | $16.7M+8.7% | $15.4M+11.6% | $13.8M-7.8% | $14.9M+0.6% | $14.9M+37.4% | $10.8M+42.8% | $7.6M-0.4% | $7.6M+13.7% | $6.7M+25.9% | $5.3M+7.4% | $4.9M+19.5% | $4.1M+26.8% | $3.3M |
| R&D Expenses | $4.5M | $4.4M-16.6% | $5.3M-8.4% | $5.7M+15.9% | $5.0M+100.4% | $2.5M+90.8% | $1.3M+75.1% | $740K+207.1% | $241K+1.5% | $237K+14.6% | $207K-55.7% | $468K+114.6% | $218K+47.8% | $148K+63.4% | $90K+154.3% | $36K |
| SG&A Expenses | $24.6M | $23.4M+8.1% | $21.6M+6.2% | $20.4M-1.2% | $20.6M+15.4% | $17.9M+48.5% | $12.0M+23.1% | $9.8M+19.2% | $8.2M+5.5% | $7.8M+30.7% | $5.9M+24.1% | $4.8M+24.3% | $3.9M+8.7% | $3.5M+33.4% | $2.7M+35.0% | $2.0M |
| Operating Income | -$1.7M | -$3.0M+53.9% | -$6.4M+37.2% | -$10.3M+4.7% | -$10.8M-53.4% | -$7.0M-460.2% | -$1.3M-314.2% | $586K-49.7% | $1.2M+258.2% | -$736K-162.3% | $1.2M+3.0% | $1.1M+13.9% | $1.0M-5.2% | $1.1M-17.6% | $1.3M+7.9% | $1.2M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $2K-44.7% | $3K+566.4% | $512-88.7% | $5K-83.9% | $28K-10.3% | $32K-13.3% | $36K |
| Income Tax | N/A | $22K+656.7% | $3K-99.9% | $4.0M+297.0% | -$2.0M-11.8% | -$1.8M-10021.4% | -$18K-113.5% | $132K-50.4% | $266K+210.2% | -$242K-167.2% | $360K+11.9% | $321K+4.7% | $307K-1.7% | $312K-32.9% | $465K-4.9% | $489K |
| Net Income | -$1.8M | -$2.6M+56.5% | -$6.1M+55.9% | -$13.7M-58.7% | -$8.7M-89.8% | -$4.6M-276.5% | -$1.2M-314.8% | $564K-38.0% | $911K+270.2% | -$535K-168.3% | $783K+3.9% | $753K+7.1% | $703K-3.1% | $726K-11.0% | $816K+15.9% | $704K |
| EPS (Diluted) | — | -$0.06+53.8% | -$0.13+56.7% | -$0.30-57.9% | -$0.19-90.0% | -$0.10-233.3% | -$0.03-400.0% | $0.01-50.0% | $0.02+300.0% | -$0.01-150.0% | $0.020.0% | $0.020.0% | $0.020.0% | $0.020.0% | $0.020.0% | $0.02 |
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
KRMD Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $28.2M+3.6% | $27.2M-4.4% | $28.5M-32.8% | $42.3M+2.5% | $41.3M+3.4% | $39.9M+187.6% | $13.9M+31.6% | $10.5M+29.1% | $8.2M-2.7% | $8.4M+15.3% | $7.3M+17.3% | $6.2M+11.0% | $5.6M+16.4% | $4.8M+39.9% | $3.4M |
| Current Assets | $20.0M+4.5% | $19.1M-5.5% | $20.3M-32.0% | $29.8M-20.1% | $37.3M-0.5% | $37.5M+215.8% | $11.9M+31.5% | $9.0M+33.2% | $6.8M-4.8% | $7.1M+20.5% | $5.9M+11.6% | $5.3M+14.3% | $4.6M+8.9% | $4.3M+41.1% | $3.0M |
| Cash & Equivalents | $8.9M-7.4% | $9.6M-16.6% | $11.5M-34.0% | $17.4M-31.3% | $25.3M-7.3% | $27.3M+365.3% | $5.9M+57.0% | $3.7M+8.2% | $3.5M-17.8% | $4.2M+64.3% | $2.6M+14.8% | $2.2M+15.4% | $1.9M+9.9% | $1.8M+32.9% | $1.3M |
| Inventory | $3.7M+31.2% | $2.8M-19.5% | $3.5M-45.6% | $6.4M+4.9% | $6.1M-10.6% | $6.8M+185.9% | $2.4M+13.5% | $2.1M+55.4% | $1.4M+30.1% | $1.0M-15.2% | $1.2M+49.8% | $819K-28.8% | $1.2M-1.5% | $1.2M+74.7% | $668K |
| Accounts Receivable | $6.2M+8.6% | $5.7M+41.4% | $4.0M+13.7% | $3.6M-0.9% | $3.6M+39.6% | $2.6M-20.5% | $3.2M+126.8% | $1.4M-5.1% | $1.5M+11.2% | $1.4M-16.8% | $1.6M-6.9% | $1.7M+56.5% | $1.1M+26.0% | $885K+23.9% | $714K |
| Total Liabilities | $11.2M+7.2% | $10.4M+28.3% | $8.1M-26.3% | $11.0M+129.7% | $4.8M+27.4% | $3.8M+42.2% | $2.6M+67.0% | $1.6M+6.0% | $1.5M+17.1% | $1.3M+26.6% | $1.0M-0.9% | $1.0M-17.7% | $1.2M-1.5% | $1.3M+31.5% | $954K |
| Current Liabilities | $8.2M+13.8% | $7.2M+61.7% | $4.5M-36.0% | $7.0M+45.2% | $4.8M+30.7% | $3.7M+52.4% | $2.4M+51.9% | $1.6M+14.0% | $1.4M+25.4% | $1.1M+60.2% | $692K-10.4% | $772K+46.9% | $525K-6.0% | $559K+77.9% | $314K |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $394K-10.3% | $439K | N/A |
| Total Equity | $17.0M+1.4% | $16.8M-17.4% | $20.4M-35.0% | $31.3M-14.2% | $36.5M+1.0% | $36.2M+221.8% | $11.2M+25.4% | $9.0M+34.2% | $6.7M-6.2% | $7.1M+13.5% | $6.3M+20.8% | $5.2M+19.2% | $4.4M+22.7% | $3.6M+43.1% | $2.5M |
| Retained Earnings | -$32.0M-9.0% | -$29.4M-26.0% | -$23.3M-143.6% | -$9.6M-951.7% | -$910K-124.9% | $3.7M-24.9% | $4.9M+13.1% | $4.3M+73.1% | $2.5M-17.7% | $3.0M+35.0% | $2.2M+50.8% | $1.5M+90.1% | $781K+1325.2% | $55K+107.2% | -$761K |
Not reported in any period shown, so not listed: Goodwill.
KRMD Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $1.4M | $462K+244.6% | -$320K+93.5% | -$4.9M+9.5% | -$5.4M-25.1% | -$4.3M-481.1% | -$743K-331.8% | $321K-78.3% | $1.5M+546.2% | -$332K-117.3% | $1.9M+131.8% | $826K-13.4% | $954K+21.6% | $785K+40.0% | $561K-45.5% | $1.0M |
| Capital Expenditures | $614K | $933K-28.1% | $1.3M+65.7% | $783K-71.6% | $2.8M+697.6% | $346K-62.4% | $921K+357.6% | $201K-32.3% | $297K+46.2% | $203K+66.8% | $122K-79.4% | $591K+213.4% | $189K-66.5% | $564K+138.6% | $236K+17.8% | $201K |
| Free Cash Flow | $777K | -$470K+70.9% | -$1.6M+71.5% | -$5.7M+30.5% | -$8.2M-75.0% | -$4.7M-180.4% | -$1.7M-1493.0% | $119K-89.9% | $1.2M+321.2% | -$535K-129.8% | $1.8M+664.0% | $235K-69.4% | $766K+246.1% | $221K-31.8% | $324K-60.8% | $828K |
| Investing Cash Flow | -$1.1M | -$950K+28.8% | -$1.3M-63.6% | -$815K+70.9% | -$2.8M-665.1% | -$366K+64.7% | -$1.0M-179.1% | $1.3M+175.7% | -$1.7M-315.5% | -$416K | N/A | -$745K-241.7% | -$218K+61.6% | -$568K-67.6% | -$339K+4.0% | -$353K |
| Financing Cash Flow | -$17K | -$221K+10.9% | -$249K-13.6% | -$219K-178.3% | $279K-89.7% | $2.7M-88.4% | $23.2M+4532.7% | $501K+3374.2% | $14K | N/A | N/A | $249K+156.6% | -$439K-910.0% | -$43K-120.4% | $213K+228.4% | -$166K |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $3K | N/A | N/A | N/A | $24K | N/A | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Dividends Paid.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
KRMD Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 62.3%-1.1pp | 63.4%+4.8pp | 58.6%+3.5pp | 55.1%-3.5pp | 58.6%-3.2pp | 61.8%-2.3pp | 64.1%+1.8pp | 62.3%+0.7pp | 61.6%-0.5pp | 62.1%+2.6pp | 59.5%-1.6pp | 61.0%-2.6pp | 63.7%-1.1pp | 64.8%-1.5pp | 66.3% |
| Operating Margin | -7.2%+11.9pp | -19.2%+16.8pp | -36.0%+2.6pp | -38.6%-8.7pp | -29.9%-24.7pp | -5.2%-7.7pp | 2.5%-4.2pp | 6.7%+12.7pp | -6.0%-15.6pp | 9.7%-0.5pp | 10.2%-1.4pp | 11.6%-2.1pp | 13.7%-6.5pp | 20.2%-4.1pp | 24.3% |
| Net Margin | -6.4%+11.6pp | -18.0%+30.1pp | -48.2%-17.1pp | -31.1%-11.6pp | -19.4%-14.4pp | -5.0%-7.4pp | 2.4%-2.8pp | 5.3%+9.6pp | -4.3%-10.7pp | 6.4%-0.3pp | 6.7%-1.4pp | 8.1%-1.3pp | 9.3%-3.4pp | 12.8%-1.5pp | 14.3% |
| Return on Equity | -15.5%+20.6pp | -36.1%+31.4pp | -67.5%-39.9pp | -27.7%-15.2pp | -12.5%-9.2pp | -3.4%-8.4pp | 5.0%-5.1pp | 10.2%+18.2pp | -8.0%-19.0pp | 11.0%-1.0pp | 12.0%-1.6pp | 13.6%-3.1pp | 16.7%-6.3pp | 23.0%-5.4pp | 28.4% |
| Return on Assets | -9.3%+12.9pp | -22.3%+26.0pp | -48.3%-27.8pp | -20.5%-9.4pp | -11.1%-8.0pp | -3.0%-7.1pp | 4.1%-4.6pp | 8.6%+15.2pp | -6.6%-15.9pp | 9.3%-1.0pp | 10.3%-1.0pp | 11.3%-1.7pp | 13.0%-4.0pp | 17.0%-3.5pp | 20.5% |
| Current Ratio | 2.44-0.2x | 2.66-1.9x | 4.55+0.3x | 4.28-3.5x | 7.79-2.4x | 10.23+5.3x | 4.94-0.8x | 5.70+0.8x | 4.88-1.5x | 6.43-2.1x | 8.54+1.7x | 6.86-2.0x | 8.82+1.2x | 7.61-2.0x | 9.60 |
| Debt-to-Equity | 0.650.0x | 0.62+0.2x | 0.400.0x | 0.35+0.2x | 0.130.0x | 0.10-0.1x | 0.24+0.1x | 0.180.0x | 0.220.0x | 0.180.0x | 0.160.0x | 0.20+0.1x | 0.090.0x | 0.12-0.3x | 0.38 |
| FCF Margin | -1.1%+3.7pp | -4.8%+15.1pp | -19.9%+9.4pp | -29.3%-9.4pp | -19.9%-13.0pp | -6.9%-7.4pp | 0.5%-6.3pp | 6.8%+11.2pp | -4.3%-19.0pp | 14.6%+12.6pp | 2.1%-6.7pp | 8.8%+5.9pp | 2.9%-2.2pp | 5.1%-11.8pp | 16.8% |
Similar Companies
Where Koru Med Sys Ranks
Frequently Asked Questions
What is Koru Med Sys's annual revenue?
Koru Med Sys (KRMD) reported $41.1M in total revenue for fiscal year 2025. This represents a 22.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Koru Med Sys's revenue growing?
Koru Med Sys (KRMD) revenue grew by 22.2% year-over-year, from $33.6M to $41.1M in fiscal year 2025.
Is Koru Med Sys profitable?
No, Koru Med Sys (KRMD) reported a net income of -$2.6M in fiscal year 2025, with a net profit margin of -6.4%.
What is Koru Med Sys's EBITDA?
Koru Med Sys (KRMD) had EBITDA of -$2.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Koru Med Sys's gross margin?
Koru Med Sys (KRMD) had a gross margin of 62.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Koru Med Sys's operating margin?
Koru Med Sys (KRMD) had an operating margin of -7.2% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Koru Med Sys's net profit margin?
Koru Med Sys (KRMD) had a net profit margin of -6.4% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Koru Med Sys's return on equity (ROE)?
Koru Med Sys (KRMD) has a return on equity of -15.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Koru Med Sys's free cash flow?
Koru Med Sys (KRMD) recorded an outflow of $470K in free cash flow during fiscal year 2025. This represents a 70.9% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Koru Med Sys's operating cash flow?
Koru Med Sys (KRMD) generated $462K in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Koru Med Sys's total assets?
Koru Med Sys (KRMD) had $28.2M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Koru Med Sys's capital expenditures?
Koru Med Sys (KRMD) invested $933K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Koru Med Sys spend on research and development?
Koru Med Sys (KRMD) invested $4.4M in research and development during fiscal year 2025.
What is Koru Med Sys's current ratio?
Koru Med Sys (KRMD) had a current ratio of 2.44 as of fiscal year 2025, which is generally considered healthy.
What is Koru Med Sys's debt-to-equity ratio?
Koru Med Sys (KRMD) had a debt-to-equity ratio of 0.65 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Koru Med Sys's return on assets (ROA)?
Koru Med Sys (KRMD) had a return on assets of -9.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Koru Med Sys's Altman Z-Score?
Koru Med Sys (KRMD) has an Altman Z-Score of 8.02, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Koru Med Sys's Piotroski F-Score?
Koru Med Sys (KRMD) has a Piotroski F-Score of 4 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Koru Med Sys's earnings high quality?
Koru Med Sys (KRMD) reported a net loss of $2.6M while generating $462K in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Koru Med Sys?
Koru Med Sys (KRMD) scores 70 out of 100 on our Financial Health Score, indicating strong standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.